Loading clinical trials...
Loading clinical trials...
A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Conditions
Interventions
BRII-179
BRII-835 (VIR-2218)
+1 more
Locations
12
China
Investigative Site 86004
Beijing, Beijing Municipality, China
Investigative Site 86009
Beijing, Beijing Municipality, China
Investigative Site 86015
Xiamen, Fujian, China
Investigative Site 86012
Foshan, Guangdong, China
Investigative Site 86001
Guangzhou, Guangdong, China
Investigative Site 86013
Guangzhou, Guangdong, China
Start Date
August 6, 2024
Primary Completion Date
December 1, 2026
Completion Date
June 1, 2027
Last Updated
December 30, 2024
Lead Sponsor
Brii Biosciences Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions